{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-normal&page=27",
    "query": {
      "condition": "HER2-normal",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 1188,
    "total_pages": 119,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-normal&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-normal&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-14T17:18:16.080Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02993068",
      "title": "Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "BARD1 Gene Mutation",
        "BRCA1 Gene Mutation",
        "BRCA2 Gene Mutation",
        "BRIP1 Gene Mutation",
        "Estrogen Receptor Negative",
        "HER2/Neu Negative",
        "MLH1 Gene Mutation",
        "MSH2 Gene Mutation",
        "MSH6 Gene Mutation",
        "PALB2 Gene Mutation",
        "PMS2 Gene Mutation",
        "Progesterone Receptor Negative",
        "RAD51C Gene Mutation",
        "RAD51D Gene Mutation",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Educational Intervention",
          "type": "OTHER"
        },
        {
          "name": "Genetic Counseling",
          "type": "OTHER"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "30 Years and older · Female only"
      },
      "enrollment_count": 5200,
      "start_date": "2017-04-18",
      "completion_date": "2028-04-18",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-11-14T17:18:16.080Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • Seattle, Washington",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02993068"
    },
    {
      "nct_id": "NCT01698918",
      "title": "Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hormone Receptor Positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study)",
          "type": "DRUG"
        },
        {
          "name": "Standard of care to treat stomatitis (Stomatitis sub-study)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 202,
      "start_date": "2013-03-07",
      "completion_date": "2021-01-13",
      "has_results": true,
      "last_update_posted_date": "2023-05-03",
      "last_synced_at": "2026-11-14T17:18:16.080Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Loma Linda, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Park Ridge",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01698918"
    },
    {
      "nct_id": "NCT00003440",
      "title": "Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HER2-negative Breast Cancer",
        "HER2-positive Breast Cancer",
        "Recurrent Breast Cancer",
        "Stage IIIC Breast Cancer",
        "Stage IV Breast Cancer"
      ],
      "interventions": [
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 580,
      "start_date": "1998-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-06-04",
      "last_synced_at": "2026-11-14T17:18:16.080Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003440"
    },
    {
      "nct_id": "NCT00105950",
      "title": "Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms, Breast"
      ],
      "interventions": [
        {
          "name": "lapatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 126,
      "start_date": "2005-03",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2015-09-28",
      "last_synced_at": "2026-11-14T17:18:16.080Z",
      "location_count": 8,
      "location_summary": "Miami, Florida • Chicago, Illinois • Zion, Illinois + 5 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Zion",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00105950"
    },
    {
      "nct_id": "NCT00580112",
      "title": "An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Trabectedin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 127,
      "start_date": "2007-06",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2014-02-25",
      "last_synced_at": "2026-11-14T17:18:16.080Z",
      "location_count": 21,
      "location_summary": "Sedona, Arizona • Denver, Colorado • Torrington, Connecticut + 18 more",
      "locations": [
        {
          "city": "Sedona",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Torrington",
          "state": "Connecticut"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Westminster",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00580112"
    },
    {
      "nct_id": "NCT00398567",
      "title": "A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "HKI-272",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Puma Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2007-04-04",
      "completion_date": "2018-03-02",
      "has_results": true,
      "last_update_posted_date": "2018-07-24",
      "last_synced_at": "2026-11-14T17:18:16.080Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Los Angeles, California • Pasadena, California + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00398567"
    },
    {
      "nct_id": "NCT01570036",
      "title": "Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Herceptin",
          "type": "DRUG"
        },
        {
          "name": "NeuVax vaccine",
          "type": "DRUG"
        },
        {
          "name": "GM-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "George E. Peoples",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 275,
      "start_date": "2013-05-21",
      "completion_date": "2018-09-28",
      "has_results": true,
      "last_update_posted_date": "2020-12-02",
      "last_synced_at": "2026-11-14T17:18:16.080Z",
      "location_count": 29,
      "location_summary": "Beverly Hills, California • Santa Monica, California • Santa Rosa, California + 22 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01570036"
    },
    {
      "nct_id": "NCT06229392",
      "title": "A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Cancer Triple Negative"
      ],
      "interventions": [
        {
          "name": "Fluzone Quadrivalent",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2026-06-01",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-11-14T17:18:16.080Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06229392"
    },
    {
      "nct_id": "NCT03206203",
      "title": "Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "Stage IV Breast Cancer",
        "HER2 Negative",
        "Invasive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2017-08-29",
      "completion_date": "2023-10-04",
      "has_results": true,
      "last_update_posted_date": "2024-12-12",
      "last_synced_at": "2026-11-14T17:18:16.080Z",
      "location_count": 6,
      "location_summary": "Washington D.C., District of Columbia • Indianapolis, Indiana • Baltimore, Maryland + 3 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03206203"
    },
    {
      "nct_id": "NCT05378464",
      "title": "Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Dendritic Cell (DC1) Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pepinemab",
          "type": "DRUG"
        },
        {
          "name": "T-Cell therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2022-05-31",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-11-14T17:18:16.080Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05378464"
    }
  ]
}